EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’s pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which …
Oertli Instrumente Acquires Majority Interest in Ophthalmic Instrument Maker Domedics AG
Oertli Instrumente announced it has acquired the majority of shares of Dattwil, Switzerland-based Domedics AG. Terms of the deal were not disclosed.https://eyewire.news/news/oertli-instrumente-acquires-majority-interest-in-ophthalmic-instrument-maker-domedics-ag
FDA Approves Samsung Bioepis and Biogen’s Byooviz Lucentis Biosimilar (ranibizumab-nuna)
Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV).
Apellis Announces Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approval
Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Based on results from the studies, the company plans to submit a new drug application (NDA) for pegcetacoplan for GA to the FDA in the first half of 2022.
Oertli Launches Updated Faros Surgical Platform
Oertli has updated its Faros surgical platform with new LED technology. The compact device for anterior and posterior segment surgery provides 45% more light output, and ensures optimal illumination and visualization, according to a company news release. Oertli’s Faros device performs cataract, vitrectomy, and glaucoma surgery. The precise flow control of the peristaltic pump is designed to make the surgeon’s work simple …
Aequus, reVision to collaborate on Stargardt disease treatment
Aequus Pharmaceuticals and reVision Therapeutics will collaborate to develop a treatment for Stargardt disease, according to a press release.In addition, the agreement grants Aequus the option to acquire the North American commercial rights to REV-0100 from reVision.
AI-based eye test could help prevent severe vision loss
Researchers from Imperial College London and University College London (UCL) carried out a clinical trial using retinal imaging technology known as Detection of Apoptosis in Retinal Cells (DARC). When tested on 113 patients in the trial, the technology was able to identify areas of the eye that were showing signs of geographic atrophy (GA) – a common condition that causes …
Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration
In posterior segment disorders characterized by the growth of abnormal blood vessels, the vascular endothelial growth factor (VEGF) protein is upregulated, which has led to the current standard-of-care treatments targeting this important pathway. Anti-VEGF agents have drastically improved treatment of neovascular age-related macular degeneration (nAMD) and diabetic retinopathy over the past 15 years. However, not all patients respond adequately to anti-VEGF …
New telemedicine approach may allow for remote treatment of DR
A novel telemedicine approach combining the high speed of 5G wireless networks and navigated retinal laser photocoagulation could allow treatment of diabetic retinopathy at a distance.
Regeneron Terminates Ocular Therapeutix Collaboration to Develop a Sustained-Release Formulation of Aflibercept
Ocular Therapeutix announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021.
- Page 1 of 2